FIELD: immunology.
SUBSTANCE: application of cytolytic T-cell, cytolytic T-cell, CAR. Invention also discloses a nucleic acid molecule, an expression vector, a cell production method, a method of treating T-cell lymphoma or leukemia.
EFFECT: present invention can find further application in therapy of oncological diseases associated with malignant T-cells.
18 cl, 29 dwg, 6 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO CONSTANT REGION OF β T-CELL RECEPTOR | 2015 |
|
RU2830064C2 |
| ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
| T-CELL RECEPTORS | 2018 |
|
RU2762255C2 |
| T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING CD70 | 2019 |
|
RU2801824C2 |
| T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
| BINDING DOMAIN | 2019 |
|
RU2829934C2 |
| CHIMERIC ANTIGENE RECEPTOR | 2019 |
|
RU2810092C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT RECEPTOR BOUND TO G-PROTEINS, AND THEIR APPLICATION | 2015 |
|
RU2762359C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
